Trial Profile
Randomised phase 2 trial of Bemcentinib in the patients with non-small cell lung cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2018
Price :
$35
*
At a glance
- Drugs Bemcentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Dec 2018 New trial record
- 26 Nov 2018 According to a BerGenBio media release, this trial is expected to begin in 2019.